Virtus Investment Advisers’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.31M Buy
16,732
+3,161
+23% +$216K 0.31% 149
2026
Q1
$877K Buy
13,571
+2,587
+24% +$182K 0.24% 156
2025
Q4
$739K Buy
10,984
+2,836
+35% +$191K 0.2% 152
2025
Q3
$598K Hold
8,148
0.17% 188
2025
Q2
$424K Buy
8,148
+643
+9% +$36.6K 0.14% 219
2025
Q1
$479K Buy
7,505
+5,309
+242% +$308K 0.13% 200
2024
Q4
$105K Sell
2,196
-1,731
-44% -$88.8K 0.08% 257
2024
Q3
$225K Hold
3,927
0.18% 187
2024
Q2
$206K Hold
3,927
0.17% 178
2024
Q1
$160K Sell
3,927
-4,652
-54% -$174K 0.11% 210
2023
Q4
$317K Hold
8,579
0.24% 128
2023
Q3
$328K Hold
8,579
0.22% 117
2023
Q2
$309K Hold
8,579
0.21% 136
2023
Q1
$328K Buy
8,579
+453
+6% +$21.2K 0.23% 132
2022
Q4
$462K Hold
8,126
0.31% 102
2022
Q3
$321K Buy
+8,126
New +$359K 0.15% 135

Other funds holding HALO

Virtus Investment Advisers's HALO Position: Q2 2026 in Review

Virtus Investment Advisers increased its Halozyme (HALO) stake by 23% in Q2 2026, buying an estimated $216K and bringing the position to 16,732 shares worth $1.31M. The position accounts for 0.31% of the portfolio, ranked #149.

Virtus Investment Advisers first reported a position in HALO in Q3 2022 and has held it in 16 quarters since. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Virtus Investment Advisers held 16,732 shares of Halozyme worth $1.31M as of Q2 2026.
  • Virtus Investment Advisers bought 3,161 Halozyme shares in Q2 2026, an estimated $216K.
  • Halozyme made up 0.31% of Virtus Investment Advisers's portfolio in Q2 2026, its #149 holding.
  • Virtus Investment Advisers first reported a position in Halozyme in Q3 2022 and has held it in 16 quarters since.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.